Meet Alfa Cytology at the Cancer R&D 2024, Nov 18-20, 2024. We look forward to connecting with you and providing expert solutions for your cancer drug development projects.

Learn More
DMPK/ADME for Cancer Therapy
Solutions
Online Inquiry

DMPK/ADME for Cancer Therapy

Drug metabolism and pharmacokinetics (DMPK), in conjunction with absorption, distribution, metabolism, and excretion (ADME), play a vital role in the development of drugs. Grasping these characteristics is essential for the effectiveness of cancer medications. Alfa Cytology, boasting profound knowledge in ADME and DMPK, furnishes dependable pharmacokinetic profiles to facilitate the advancement of cancer therapy effectively.

Introduction to DMPK/ADME

When we talk about drug metabolism, we mainly focus on how the liver changes drugs. There are two main phases: Phase I, where drugs are altered through processes like oxidation or reduction to make it easier for the body to remove or prepare them for Phase II. Phase II involves joining the drug or its altered forms to other molecules to help the body get rid of them. Now, "PK" stands for "Pharmacokinetics." It's all about studying how drugs move into, around, and out of the body over time.

Fig.1 Understanding Pharmacodynamics and Pharmacokinetics in Drug Action. (Bates, S. E., 2014)

Drug Metabolism and Pharmacokinetics (DMPK) are crucial in finding out which drugs might work well for treatments. We look at how drugs are absorbed, distributed, broken down, and removed from the body, as well as their potential side effects. Understanding these processes helps us determine which drugs might be promising for further development. DMPK and ADME are both important in studying how drugs work inside the body, although they have their own unique focuses.

Relationship

Common Goal

Both DMPK and ADME aim to understand the processes of drug metabolism.distribution, transfommation, and excretion in the body to evaluate drug efficacy and safety.

Holistic Assessment

Combining DMPK and ADME provides a more complete understanding of the dynamic changes of drugs in the body, thereby guiding drug development, clinical use,and optimization of therapeutic regimens.

Differences

Focus

DMPK focuses on the metabolic and kinetic properties of drugs, including biotransformation, metabolic pathways, and enzyme systems, while ADME covers the entire spectrum of absorption, distribution, metabolism, and excretion.

Evaluation Perspective

DMPK emphasizes drug biotransformation and metabolic dynamics, such as metabolites, pathways, and enzyme interactions. ADME focuses on pharmacokinetic behaviors, including absorption rates, tissue distribution, and clearance.

Our Services

In the field of oncology drugs, DMPK/ADME plays a pivotal role and they are the cornerstones for the development of new drug compounds. Alfa Cytology, as a company specializing in cancer services, offers a comprehensive range of DMPK and ADME services.

In vitro ADME for cancer Drugs

In vitro screening is pivotal for optimizing drug candidates for ADME characterization. Identifying promising candidates beforehand accelerates development cycles, cuts costs, streamlines discovery pipelines, and informs subsequent preclinical studies.

In vivo PK for cancer Drugs

DMPK plays a crucial role in drug discovery and development by providing insights into drug behavior in vivo. This knowledge aids in optimizing drug design, dosing regimens, and identifying safety concerns.

Alfa Cytology's specialists are poised to support the success of your cancer therapy program, offering the necessary capabilities and expertise for seamless program integration. Our assistance streamlines drug discovery, saving time, costs, and resources. Should you wish to explore DMPK/ADME for cancer therapy further, please don't hesitate to contact us.

Reference

  1. Bates, S. E. (2014). The language of pharmacodynamics. Clinical Cancer Research, 20(10), 2524-2524.

For research use only.